» Articles » PMID: 22136259

Controlled Release Pulmonary Administration of Curcumin Using Swellable Biocompatible Microparticles

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2011 Dec 6
PMID 22136259
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

This study involves a promising approach to achieve sustained pulmonary drug delivery. Dry powder particulate carriers were engineered to allow simultaneous aerosol lung delivery, evasion of macrophage uptake, and sustained drug release through a controlled polymeric architecture. Chitosan grafted with PEG was synthesized and characterized (FTIR, EA, DSC and 2D-XRD). Then, a series of respirable amphiphilic hydrogel microparticles were developed via spray drying of curcumin-loaded PLGA nanoparticles with chitosan-grafted-PEG or chitosan. The nanoparticles and microparticles were fully characterized using an array of physicochemical analytical methods including particle size, surface morphology, dynamic swelling, density, moisture content and biodegradation rates. The PLGA nanoparticles and the hydrogel microspheres encapsulating the curcumin-loaded PLGA nanoparticles showed average size of 221-243 nm and 3.1-3.9 μm, respectively. The developed carriers attained high swelling within a few minutes and showed low moisture content as dry powders (0.9-1.8%), desirable biodegradation rates, high drug loading (up to 97%), and good sustained release. An aerosolization study was conducted using a next generation impactor, and promising aerosolization characteristics were shown. In vitro macrophage uptake studies, cytotoxicity and in vitro TNF-α assays were performed for the investigated particles. These assays revealed promising biointeractions for the respirable/swellable nano-micro particles developed in this study as potential carriers for sustained pulmonary drug delivery.

Citing Articles

Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.

Kesharwani P, Halwai K, Jha S, Mughram M, Salman Almujri S, Almalki W Mol Cancer. 2024; 23(1):244.

PMID: 39482651 PMC: 11526716. DOI: 10.1186/s12943-024-02163-z.


Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery.

Mansour H, Muralidharan P, Hayes Jr D J Aerosol Med Pulm Drug Deliv. 2024; 37(4):202-218.

PMID: 39172256 PMC: 11465844. DOI: 10.1089/jamp.2024.29117.mk.


Global research status and trends of interactions between Traditional Chinese medicine and pulmonary fibrosis: A new dawn in treatment.

Wei B, Li H, Wang C, Hu J Heliyon. 2024; 10(14):e34592.

PMID: 39149021 PMC: 11325230. DOI: 10.1016/j.heliyon.2024.e34592.


Light-responsive polymeric nanoparticles for retinal drug delivery: design cues, challenges and future perspectives.

Guidi L, Cascone M, Rosellini E Heliyon. 2024; 10(5):e26616.

PMID: 38434257 PMC: 10906429. DOI: 10.1016/j.heliyon.2024.e26616.


Recent Developments in Aerosol Pulmonary Drug Delivery: New Technologies, New Cargos, and New Targets.

Woodward I, Fromen C Annu Rev Biomed Eng. 2024; 26(1):307-330.

PMID: 38424089 PMC: 11222059. DOI: 10.1146/annurev-bioeng-110122-010848.


References
1.
Laube B . The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care. 2005; 50(9):1161-76. View

2.
El-Sherbiny I, Smyth H . Novel cryomilled physically cross-linked biodegradable hydrogel microparticles as carriers for inhalation therapy. J Microencapsul. 2010; 27(8):657-68. DOI: 10.3109/02652041003739840. View

3.
Oberdorster G . Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ Health. 2001; 74(1):1-8. DOI: 10.1007/s004200000185. View

4.
Dickinson P, Howells S, Kellaway I . Novel nanoparticles for pulmonary drug administration. J Drug Target. 2001; 9(4):295-302. DOI: 10.3109/10611860108997937. View

5.
Hirano S, Tsuchida H, Nagao N . N-acetylation in chitosan and the rate of its enzymic hydrolysis. Biomaterials. 1989; 10(8):574-6. DOI: 10.1016/0142-9612(89)90066-5. View